Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

PURPOSE: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. PATIENTS AND METHODS: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative advanced breast cancer previously treated with ≤2 prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Nicholas C., Balmaña, Judith, Poncet, Coralie, Goulioti, Theodora, Tryfonidis, Konstantinos, Honkoop, Aafke H., Zoppoli, Gabriele, Razis, Evangelia, Johannsson, Oskar T., Colleoni, Marco, Tutt, Andrew N., Audeh, William, Ignatiadis, Michail, Mailliez, Audrey, Trédan, Olivier, Musolino, Antonino, Vuylsteke, Peter, Juan-Fita, Maria Jose, Macpherson, Iain R.J., Kaufman, Bella, Manso, Luis, Goldstein, Lori J., Ellard, Susan L., Láng, István, Jen, Kai Yu, Adam, Virginie, Litière, Saskia, Erban, John, Cameron, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530899/
https://www.ncbi.nlm.nih.gov/pubmed/34301749
http://dx.doi.org/10.1158/1078-0432.CCR-21-0310

Ejemplares similares

Ejemplares similares